Last reviewed · How we verify

NCT07491471: BEAD-T1D

Clinican BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes

Withdrawn NA Last updated 24 March 2026
What this trial tests

NA trial testing Intervention to increase diabetes technology prescriptions in Type 1 Diabetes (T1D). Withdrawn.

Timeline
15 August 2025
Primary endpoint
15 September 2026
30 September 2026

Quick facts

Lead sponsorStanford University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Start date15 August 2025
Primary completion15 September 2026
Estimated completion30 September 2026

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

18 and older, any sex, with Type 1 Diabetes (T1D). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. This proposed research will (1) address the gap in knowledge of barriers and promoters in youth working with clinicians to identify and address factors associated with diabetes technology uptake and utilization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes (T1D)

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07491471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing